Since tamoxifen is commonly used for the treatment of ERα+/HER2- breast cancer, we thus investigated whether loss of Frmd8 affects sensitivity of mammary tumors to tamoxifen treatment in mice. This evidence concerns the gene ERBB2 and breast carcinoma.